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Background—Firefighters exposed to World Trade Center (WTC) dust have developed chronic 
rhinosinusitis (CRS) and abnormal forced expiratory volume in 1 second (FEV1). Overlapping but 
distinct immune responses may be responsible for the clinical manifestations of upper and lower 
airway injury. We investigated whether a panel of inflammatory cytokines, either associated or not 
associated with WTC-LI, can predict future chronic rhinosinusitis disease and its severity.
Methods—Serum obtained within six months of 9/11/2001 from 179 WTC exposed firefighters 
presenting for subspecialty evaluation prior to 3/2008 was assayed for 39 cytokines. The main 
outcomes were medically managed CRS (N=62) and more severe CRS cases requiring sinus 
surgery (N=14). We tested biomarker-CRS severity association using ordinal logistic regression 
analysis.
Results—Increasing serum IL-6, IL-8, GRO and neutrophil concentration reduced the risk of 
CRS progression. Conversely, increasing TNF-α increased the risk of progression. In a 
multivariable model adjusted for exposure intensity, increasing IL-6, TNF-α and neutrophil 
concentration remained significant predictors of progression. Elevated IL-6 levels and neutrophil 
counts also reduced the risk of abnormal FEV1 but in contrast to CRS, increased TNF-α did not 
increase the risk of abnormal FEV1.
Conclusions—Our study demonstrates both independent and overlapping biomarker 
associations with upper and lower respiratory injury, and suggests that the innate immune 
response may play a protective role against CRS and abnormal lung function in those with WTC 
exposure.
Keywords
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INTRODUCTION
The World Trade Center (WTC) collapse produced vast quantities of respirable dust 
affecting Fire Department of New York (FDNY) rescue workers, other exposed workers, 
lower Manhattan residents and children (1–6). WTC dust was alkaline (pH, 9.2–11.5) and 
was comprised of metals, radionuclides, ionic species, asbestos, polycyclic aromatic 
hydrocarbons, polychlorinated biphenyls, polychlorinated dibenzodioxines and other 
potentially hazardous materials. The bulk of WTC particulate matter (PM) was larger than 
10μm, which usually is filtered in the nasopharynx (7). However, the body’s usual protective 
barriers were overwhelmed, producing intense dust exposure to both the upper and lower 
airways. (2).
A high incidence of upper and lower airway respiratory disorders has persisted in WTC 
exposed firefighters years after 9/11 (8). Chronic rhinosinusitis (CRS) has been the most 
common manifestation of upper airway injury in this population. Prior to 9/11, only 4.4% of 
FDNY firefighters reported rhinosinusitis symptoms. By one year after 9/11, self-reported 
rhinosinusitis symptoms had increased 10-fold (45.1%) and persisted above 30% well into 
the fifth year after 9/11 (9, 10). Numerous disability claims arising from respiratory 
disorders such as CRS have had substantial financial ramifications (11).
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Shared upper and lower airway immune response is well established in the spectrum of 
atopic rhinosinusitis and allergic asthma (12–14) and as a cause of chronic cough syndrome 
(15). CRS in the FDNY firefighter cohort exists both in isolation and in accompaniment 
with WTC lower airway injury (WTC-LI) (16), portending overlapping but distinct immune 
pathogenesis of irritant induced upper and lower airway injury. The pathophysiology of CRS 
after occupational irritant exposure has not been well characterized.
We have previously reported inflammatory biomarkers that are predictive of future 
abnormal lung function in the FDNY firefighter cohort (17). No biomarker studies have 
been published that predict the long-term outcome of upper airway disease in this 
population. We investigated whether a panel of inflammatory cytokines, either associated or 
not associated with WTC-LI, can predict future chronic rhinosinusitis disease and its 
severity.
METHODS
Study Design
All WTC exposed FDNY workers were enrolled in the Medical Monitoring and Treatment 
Program. FDNY workers (N=1,720) who complained of any respiratory symptoms between 
October 1, 2011 and March 10, 2008 were systematically sent for subspecialty pulmonary 
evaluation (SPE). We performed a nested case-cohort study on firefighters using this 
baseline cohort of 1,720 exposed, symptomatic workers. Study subgroups were derived from 
the baseline cohort after excluding for patients with prior lung or sinus disease. Figure 1. 
Chronic rhinosinusitis (CRS) in our study was defined as nasal and/or sinus inflammation, 
with recurrence of symptoms after re-exposure to irritants (16). The diagnosis of chronic 
rhinosinusitis was determined by the evaluating physician and was confirmed by sinus CT 
scan and treated medically with nasal saline lavage, nasal steroids decongestant and proton 
pump inhibitor (18). The time of CRS diagnosis was abstracted from the FDNY electronic 
medical record (FDNY-eMR). Of the 179-study patients, whose serum were available for 
biomarker assay, 76 developed CRS; 62 were medically managed and 14 were refractory to 
medical management and elected to have sinus surgery. Refractory was defined as requiring 
at least 3 months of medical management with persistent symptoms, despite reported 
medication adherence that substantially interfered with the patient’s quality of life. Once 
medical management failed, patients were referred to ENT subspecialty clinic. For our 
analysis of progression, we confirmed in the FDNY-eMR an ordered progression from no 
CRS prior to 9/11/01 to post-9/11/01 medically managed sinusitis and, when refractory to 
medical management, to surgically managed sinusitis. Subjects signed informed consents 
approved by the institutional review boards of Montefiore Medical Center (#07–09–320) 
and New York University (#11–00439).
Demographics
Age, race and years of service at FDNY were obtained from the FDNY-WTC-monitoring 
database. Body mass indices (BMIs) were calculated from height and weight measured at 
the time of serum draw. Degree of exposure was self-reported at the first FDNY-WTC-
monitoring and was categorized using the FDNY-WTC Exposure Intensity Index (Arrival 
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Time): i. Presented on the morning of 9/11/2001 ii. Arrived between afternoon on 9/11/2001 
and 9/12/2001 (17, 19). Those arrived after day-three were excluded from analysis as a 
result of their low numbers in this sample. Subjects underwent spirometry at the time of 
serum collection as previously described (17, 19, 20).
Serum Sampling and Analysis
Blood drawn at the first post-9/11 FDNY-WTC monitoring exam was processed as 
described.17 Serum was thawed once at 4°C and assayed using a pro-inflammatory panel 
(39-Plex including EGF, Eotaxin, FGF-2, Flt-3 ligand, Fractalkine, G-CSF, GM-CSF, GRO, 
IFN-α2, IFN-γ, IL-10, IL-12 (p40), IL-12 (p70), IL-13, IL-15, IL-17, IL-1Rα, IL-1α, IL-1β, 
IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IP-10, MCP-1, MCP-3, MDC (CCL22), 
MIP-1α, MIP-1β, TGF-α, TNF-α, TNF-β, VEGF, sCD40L, sIL-2Rα, Millipore, Billerica, 
MA) and Metabolic Hormone Panel (13-Plex including GM-CSF, IFN-γ, IL-10, IL-15, 
IL-18, IL-2, IL-6, IL-7, IL-8, IP-10, KC-like, MCP-1, TNF-α, Millipore, Billerica, MA) 
according to manufacturer’s instructions (Millipore) and analyzed on a Luminex 200IS 
(Luminex Corporation).
Statistical Analysis
We tested normality using the Shapiro-Wilk test and Q-Q plots. Jonckheere-Terpstra or 
Wilcoxon rank-sum tested for group comparisons. The Chi-squared or Fisher’s exact tested 
for inferences on proportions. Ordinal logistic regression analysis with the proportional-odds 
model tested association between inflammatory biomarkers and progressive sinusitis 
severity. The approximate likelihood-ratio test of proportionality of odds and the Brant test 
of parallel lines assumption assessed model appropriateness. Since biomarkers were severely 
skewed, we log-transformed them before including them as continuous covariates in the 
model. Logistic regression was used to assess the association between biomarkers and 
abnormal forced expiratory volume in 1 second (FEV1 less than lower limit of normal). A 
two-sided P-value less than 0.05 was considered significant. All analyses were performed 
with STATA/SE version 12.1 (StataCorp LP, College Station, TX).
RESULTS
Study Design and demographics
The derivation of medical CRS cases, surgical CRS cases and controls with no sinusitis 
during the study period is described in Figure 1. Demographics of the baseline cohort and all 
study subgroups are shown in Table 1. Serum obtained for biomarker analysis was drawn on 
average 2 to 3 months post 9/11. There was no significant difference in the time to serum 
collection amongst these subgroups (P=0.118). Cases and controls had similar age at 9/11, 
years of firefighting service, body mass index, racial distribution and WTC exposure 
intensity. There were no significant differences in spirometric parameters including FEV1 
and FEV1/FVC in cases versus controls.
Sinusitis incidence and overlap with abnormal FEV1
Kaplan-Meier estimator was used to assess the cumulative proportion of CRS. The incidence 
of CRS steadily increased over study period, Figure 2 Panel A. We examined the proportion 
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of the study cohort with sinusitis alone, abnormal FEV1 alone or sinusitis with abnormal 
FEV1. Fourteen percent (25/179) had both diagnoses, 28% (51/179) had only sinusitis and 
20% (35/179) had only abnormal FEV1, Figure 2 panel B.
Characteristics of Chronic Rhinosinusitis
The median time from 9/11 to CRS diagnosis was between 39 and 40 months in medical and 
surgical cases. The subspecialty pulmonary evaluation (SPE) spirometery occurred 7 months 
before the diagnosis of CRS in the medically managed cases and 4 months after the 
diagnosis of CRS in surgical cases, Table 2. Eighty three percent of CRS cases (63/76) had 
CT scans available for analysis including 50 medical and 13 surgical CRS cases. The 
median time from 9/11 to sinus CT scan was 77 months in both medical and surgical cases, 
respectively (P=0.322). Polypoid pathology on CT scan was more prevalent in surgical than 
medical cases; 46% (6/13) of surgically and 10% (5/50) of medically managed CRS patients 
had polypoid sinusitis (P=0.007).
Univariable Ordinal Logistic Regression
Assuming an ordered progression of severity from no sinusitis to medically managed 
sinusitis to sinusitis requiring surgery, we modeled biomarker ability to predict sinus disease 
status. We included a panel of 39 cytokines, neutrophil concentration and potential 
confounders such as age, BMI and exposure intensity in the initial analysis. Interleukin-6 
(IL-6), interleukin-8 (IL-8), tumor necrosis factor-alpha (TNF-α), growth-regulated 
oncogene (GRO), neutrophil counts and BMI had a P-value less than 0.2 and were therefore 
included in the multivariable ordinal logistic model, Table 3.
Multivariable Ordinal Regression Model
After adjustment for exposure intensity, IL-6, TNF-α and neutrophil concentration made it 
into the final model, Table 4. Increasing IL-6 and neutrophil counts increased the odds of 
being in the control, non-sinusitis group. With every 1 log10 pg/mL increase in IL-6, the 
probability of being in the control group increased by 10.6% while the probabilities of being 
in the medical and surgical sinusitis groups decreased by 7.8% and 2.8%, respectively. 
Similarly, with every 1,000 cells/μL increase in neutrophil count, the probability of being in 
the control group increased by 8.8% while the probabilities of being in the medical and 
surgical sinusitis groups decreased by 6.5% and 2.3%, respectively. Conversely, elevated 
TNF-α levels increased the odds of having surgically managed sinusitis. Every 1 
log10pg/mL increase in TNF-α level resulted in a 20.4% lower probability of being in the 
control group, 15.1% higher probability of being in the medical sinusitis group and 5.3% 
higher probability of being in the surgical group.
Biomarkers of Chronic Rhinosinusitis with Polyps
Since surgical patients had a 7.7 fold (95% CI: 1.8–32) increased odds of sinus polyps we 
investigated biomarkers of polyps in this cohort. We observed that increasing serum eotaxin, 
interferon-gamma (IFN-γ), interleukin-4 (IL-4), interleukin-13 (IL-13), vascular endothelial 
growth factor (VEGF), and neutrophil concentration reduced the risk of having CRS with 
polyps. Conversely, increasing eosinophil concentration increased the risk of CRS with 
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polyps, Table 5. In a multivariable model adjusted for exposure intensity, each 1 log10pg/mL 
increase in IFN-γ and IL-4 decreased the odds of having sinus polyps by 96% (95% CI: 
0.00–0.99) and 80% (95% CI: 0.06–0.75) respectively. Each 1,000 cells/μL increase of 
neutrophil count was associated with 96% (95% CI: 0.01–0.48) decrease the odds of sinus 
polyps while each 10 cells/μL increase of eosinophil count increased the risk of developing 
polyps by 15% (95%CI: 1.03–1.27), Table 6.
Biomarkers of Sinus Disease as Predictors of FEV1<LLN
We have previously reported biomarkers of inflammation that predict FEV1 below the lower 
limit of normal (LLN) in WTC exposed firefighters, and previously reported that 
macrophage derived chemokine (MDC) and granulocyte macrophage colony stimulating 
factor (GM-CSF) increased the risk of abnormal FEV1 years later. We therefore investigated 
if inflammatory biomarkers of sinus disease predicted abnormal FEV1 in this cohort. We 
observed that each 1 log10pg/mL increase in IL-6 decreased the odds of abnormal FEV1 by 
65% (95% CI: 0.19–0.62) and that each 1,000 cells/μL increase of neutrophil count was 
associated with 40% decrease in the risk of abnormal FEV1 (95% CI: 0.43–0.83) in a model 
adjusted for exposure, BMI, age, MDC and GM-CSF. TNF-α levels didn’t have statistically 
significant association with lung function in this cohort.
DISCUSSION
Years after 9/11, a high incidence of both upper and lower airway respiratory disorders has 
persisted in WTC exposed firefighters (8), with CRS representing both the most common 
manifestation of upper airway injury in this cohort and a condition of substantial morbidity 
(11). The FDNY has reported that 80% of previously healthy firefighters complained of 
rhinosinusitis symptoms the first day after 9/11/2001, 25% during the first year after 
exposure, and 32% during the next 2–4 years (21). In our study cohort who presented to the 
subspecialty pulmonary evaluation, 42% of WTC exposed firefighters were diagnosed with 
CRS, 4 times higher than physician diagnosed sinusitis in the total cohort (N=10,943) (22).
Whereas we have previously reported biomarkers of inflammation predicting abnormal 
FEV1 in WTC-exposed firefighters, this is the first study to report a panel of inflammatory 
biomarkers that predict both future CRS disease and its progression or severity in this 
population. Specifically, IL-6 and neutrophil concentration were found to be protective 
against CRS, whereas TNF-α was a risk factor for CRS progression or severity. 
Interestingly, in this same group of patients using identical blood samples, increased IL-6 
levels and neutrophil counts were likewise protective against an abnormal FEV1. In contrast, 
TNF-α was not a risk factor for an abnormal FEV1 post-9/11 (17).
That we found both independent (TNF-α) and overlapping (IL-6, neutrophil counts) 
biomarker association with irritant-induced upper and lower airway injury suggests shared 
but distinct immune pathways. Indeed, there appears to be considerable clinical overlap 
between CRS and lower airway injury as WTC-LI was a common comorbidity of CRS in 
this cohort. Twenty five out of 79 (32%) previously healthy firefighters who developed CRS 
also developed obstructive airway dysfunction post-9/11. This finding is consistent with a 
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prior report that 40% of WTC rescue workers were diagnosed with both CRS and 
obstructive airway disease post-9/11 (23).
The one-airway or unified airway concept linking the upper and lower airways is already a 
well recognized and accepted in asthma and allergic rhinitis (12, 13) and in chronic cough 
syndrome (15). Numerous cross-sectional and retrospective studies have demonstrated that 
allergic rhinitis is a risk factor for the presence of asthma (24). Potential mechanisms linking 
these upper and lower airway disease states are the nasobronchial neural reflex (airway 
hyperreactivity), drainage of pro-inflammatory material from the nose to the lungs (common 
allergen), loss of protective function of the nose, and inflammatory processes characterized 
by eosinophilia and local IgE production (14, 25, 26).
Several studies by Braunstahl (27, 28) have shown that stimulation with antigen at one 
respiratory site can result in expression of inflammatory cytokines at a location distant from 
the site of stimulation. The activation of Th2 lymphocytes in the nose can lead to the 
differentiation and activation of immune cells from precursors in the nasal mucosa and bone 
marrow, leading to recruitment of these newly generated cells throughout the upper and 
lower airways (14). These findings suggest that there is “inflammatory crosstalk” occurring 
throughout a “unified” upper and lower airway. However the pathophysiology of CRS and 
WTC-LI after occupational irritant exposure has not been previously described.
The biomarkers associated with CRS and/or WTC-LI identified in this study are known to 
be important mediators of the innate immune system. This is consistent with studies 
suggesting that the innate immune response plays an important role in the pathogenesis of 
CRS as well as obstructive airway disease (29–31). Interestingly, we found neutrophil 
concentration to be protective of both CRS and abnormal FEV1. A recent genome-wide 
association study (GWAS) demonstrated an association between polymorphisms of the 
neutrophil’s acyloxyacyl hydrolase (AOAH) gene with CRS in two independent populations 
(32, 33). The AOAH gene, which is known to contribute to the host defense against bacterial 
LPS, has also been linked to asthma (34, 35). It may appear counter-intuitive that 
neutrophils, which are conventionally agents of inflammation, were a protective biomarker 
for CRS and WTC-LI in our study. However, recent investigations have indeed supported 
the concept that anti-inflammatory cascades can be mediated by neutrophils early in the 
innate immune response (36, 37).
In our investigation, IL-6 was identified as a protective biomarker for both sinusitis and 
abnormal FEV1 as well. Although many IL-6 related gene variants have previously been 
associated with conditions such as asthma and COPD (38, 39), studies demonstrating 
association between IL-6 polymorphisms and susceptibility to CRS have been rare. 
Interestingly, cause-effect studies using transgenic mice have pointed to a dual role for IL-6 
in lower airway diseases; 1) enhancing allergic airway inflammation and 2) protecting 
against airway hyperreactivity/inflammation (40–42).
TNF-α is a cytokine that is thought to play a central role in pathogenesis in CRS (43, 44). In 
severe CRS, TNF-α synergizes with Th1 and Th2 to induce a chronic inflammatory state 
(45, 46). Multiple studies showed that single nucleotide polymorphisms (SNPs) in TNF-α 
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have been associated with nasal polyps (47–49). In our cohort, elevated TNF-α levels were a 
risk factor for severe sinusitis (typically polypoid on CT) but not WTC-LI. Further 
investigation is required to assess if TNF-α directly contributes to the inflammatory cascade 
in WTC-related CRS.
The traditional classification of allergic CRS into CRS with polyps versus without polyps is 
useful in the general population in whom the presence of polyps is strongly associated with 
sensitivity to aspirin or nonsteroidal anti-inflammatory drugs. Our cohort is unique in that 
development of CRS was provoked by massive exposure to combustion byproducts, with 
pathophysiology that could potentially be different from classical allergic CRS. There is a 
suggestion that the cytokines that reduced the risk of developing polyps are different from 
the cytokines that reduced the risk of CRS progression even though increasing blood PMN 
were protective biomarkers for both conditions. Alternately, increasing eosinophil 
concentration was a strong risk factor for polyps but not CRS progression. This suggests 
overlapping but distinct pathways to CRS progression and sinus polyps.
This study has several limitations. This is an exploratory study using a panel of 
inflammatory cytokines in this longitudinally followed cohort. The findings of this 
investigation need to be validated in lager studies and animal models. Our FDNY 
firefighters cohort is unique as they had massive acute exposure to WTC dusts. This limits 
the generalizability of these finding to other study populations with lower level PM exposure 
produced by ambient air pollution. However this is at the same time a strength of our paper 
since we can make a safe assumption that the etiology of sinusitis was WTC dust. We did 
not have an unexposed control group to compare and therefore we could not determine the 
direct effect of WTC-PM exposure on serum biomarkers. In addition, there is no good 
surrogate measure to estimate exposure prior to 9/11 since all individual firefighters would 
have had different rate of exposure even in each fire runs. Replication of these findings in 
other longitudinally followed populations with and without PM exposure will be important 
to demonstrate the generalizability of our findings.
Our study demonstrates distinct but overlapping biomarker association between upper and 
lower airway injury, and suggests that a common inflammatory pathway may be shared by 
CRS and lung disease caused by WTC exposure. The potential relationship between irritant-
induced CRS and lung injury may underlie preventive and therapeutic strategies for these 
conditions by modulating inflammation.
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Abbreviations
CRS chronic rhinosinusitis
FDNY Fire Department City of New York
FEV1 forced expiratory volume in 1 second
GRO growth-regulated oncogene
IL-6 Interleukin-6
IL-8 interleukin-8
LLN lower limit of normal
MME medical monitoring entry
NHANES National Health and Nutrition Examination Survey
PFT pulmonary function test
PM particulate matter
PMN Polymorphonuclear neutrophil
SPE subspecialty pulmonary evaluation
TNF-α tumor necrosis factor-alpha
WTC World Trade Center
WTC-LI World Trade Center-related lower airway injury
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Figure 1. 
Study design. WTC=World Trade Center; FDNY=Fire Department City of New York; 
FEV1 = forced expiratory volume in 1 second; NHANES=National Health and Nutrition 
Examination Survey
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Figure 2. 
A. Kaplan-Meier estimator was used to assess the cumulative proportion of CRS. The 
incidence of CRS steadily increased over study period. B. We examined the proportion of 
the study cohort with sinusitis alone, abnormal FEV1 alone or sinusitis with abnormal FEV1. 
Fourteen percent (25/179) had both diagnoses, 28% (51/179) had only sinusitis and 20% 
(35/179) had only abnormal FEV1.
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